Press Releases IN8bio, Inc.

Equities

INAB

US45674E1091

Delayed Nasdaq Other stock markets 01:18:44 2024-06-03 pm EDT			5-day change	1st Jan Change
1.11 ^USD	-6.72%		+5.71%	-19.57%

May. 24	IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	MT
May. 13	HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting	06:05am	AQ
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024	May. 24	AQ
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting	May. 23	AQ
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress	May. 14	AQ
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024	May. 13	AQ
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	May. 09	AQ
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	Apr. 30	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	Apr. 25	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	Apr. 24	AQ
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	Apr. 16	AQ
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	Apr. 09	AQ
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	Mar. 14	AQ
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	Mar. 05	AQ
IN8bio to Present at Upcoming Investor Conferences	Feb. 26	BU
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	Feb. 14	AQ
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals	Jan. 04	AQ
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	Dec. 11	AQ
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement	Dec. 11	AQ
IN8bio Appoints Dr. Corinne Epperly to Board of Directors	Dec. 07	AQ
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia	Dec. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IN8bio, Inc.

Equities

INAB

US45674E1091

Press Releases

Filters